WO2003048205A3 - Proteines a activite inhibitrice de l'il-6 - Google Patents

Proteines a activite inhibitrice de l'il-6 Download PDF

Info

Publication number
WO2003048205A3
WO2003048205A3 PCT/FR2002/004171 FR0204171W WO03048205A3 WO 2003048205 A3 WO2003048205 A3 WO 2003048205A3 FR 0204171 W FR0204171 W FR 0204171W WO 03048205 A3 WO03048205 A3 WO 03048205A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibiting activity
novel proteins
proteins
medicine
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/004171
Other languages
English (en)
Other versions
WO2003048205A2 (fr
Inventor
Jean-Yves Blay
Laurent Alberti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Centre Léon Bérard
Hospices Civils de Lyon
Université Claude Bernard Lyon 1
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Centre Léon Bérard
Hospices Civils de Lyon
Université Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Centre Léon Bérard, Hospices Civils de Lyon, Université Claude Bernard Lyon 1 filed Critical Institut National de la Santé et de la Recherche Médicale
Priority to EP02804246A priority Critical patent/EP1451222B1/fr
Priority to JP2003549392A priority patent/JP2005524606A/ja
Priority to DE60228878T priority patent/DE60228878D1/de
Priority to AU2002365646A priority patent/AU2002365646A1/en
Priority to US10/496,793 priority patent/US7414024B2/en
Publication of WO2003048205A2 publication Critical patent/WO2003048205A2/fr
Publication of WO2003048205A3 publication Critical patent/WO2003048205A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a pour objet des protéines à activité inhibitrice de l'IL-6, ainsi que leur utilisation et l'utilisation de protéines comprenant au moins la séquence en acides aminés SEQ ID N° 4 comme médicament et, en particulier, comme agent anticancéreux.
PCT/FR2002/004171 2001-12-04 2002-12-04 Proteines a activite inhibitrice de l'il-6 Ceased WO2003048205A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02804246A EP1451222B1 (fr) 2001-12-04 2002-12-04 Proteines a activite inhibitrice de l'il-6
JP2003549392A JP2005524606A (ja) 2001-12-04 2002-12-04 Ｉｌ−６阻害活性を有する新規のタンパク質
DE60228878T DE60228878D1 (de) 2001-12-04 2002-12-04 Proteine mit il-6 inhibitorischer wirkung
AU2002365646A AU2002365646A1 (en) 2001-12-04 2002-12-04 Novel proteins with il-6 inhibiting activity
US10/496,793 US7414024B2 (en) 2001-12-04 2002-12-04 Proteins with IL-6 inhibiting activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/15623 2001-12-04
FR0115623A FR2833011B1 (fr) 2001-12-04 2001-12-04 Nouvelle proteine a activite inhibitrice de l'il-6

Publications (2)

Publication Number Publication Date
WO2003048205A2 WO2003048205A2 (fr) 2003-06-12
WO2003048205A3 true WO2003048205A3 (fr) 2004-01-22

Family

ID=8870067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/004171 Ceased WO2003048205A2 (fr) 2001-12-04 2002-12-04 Proteines a activite inhibitrice de l'il-6

Country Status (8)

Country Link
US (1) US7414024B2 (fr)
EP (1) EP1451222B1 (fr)
JP (1) JP2005524606A (fr)
AT (1) ATE407947T1 (fr)
AU (1) AU2002365646A1 (fr)
DE (1) DE60228878D1 (fr)
FR (1) FR2833011B1 (fr)
WO (1) WO2003048205A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JP5033643B2 (ja) * 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
US20090202475A1 (en) * 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
SG178190A1 (en) * 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
EP3009518B1 (fr) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Procédé permettant de prédire le pronostic post-thérapie d'un patient atteint de sclérose en plaques à périodes progressives et rémittentes (spppr) et procédé permettant de déterminer l'applicabilité d'une nouvelle thérapie
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
EP3620531A4 (fr) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
WO2019078344A1 (fr) 2017-10-20 2019-04-25 学校法人兵庫医科大学 Composition médicinale contenant un anticorps du recepteur anti-il -6 pour prévenir l'adhérence post-chirurgicale
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019004A1 (fr) * 1993-02-19 1994-09-01 Genentech, Inc. Antagonistes de ligands utilises dans le traitement du cancer du sein
WO1995013393A1 (fr) * 1993-11-08 1995-05-18 Fred Hutchinson Cancer Research Center Cytokines hybrides
WO1997010338A1 (fr) * 1995-09-12 1997-03-20 Chiron Corporation Antagoniste ameliore du recepteur de l'interleukine 6
US5723120A (en) * 1992-10-20 1998-03-03 Chiron Corporation Method of treating an IL-6 related disease with interleukin-6 receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
EP0928293A1 (fr) * 1996-06-20 1999-07-14 Koster, Henk W. Peptides derives de l'il-6 et du recepteur de l'il-6 presentant une activite agoniste ou antagoniste vis-a-vis de l'il-6
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723120A (en) * 1992-10-20 1998-03-03 Chiron Corporation Method of treating an IL-6 related disease with interleukin-6 receptor antagonists
WO1994019004A1 (fr) * 1993-02-19 1994-09-01 Genentech, Inc. Antagonistes de ligands utilises dans le traitement du cancer du sein
WO1995013393A1 (fr) * 1993-11-08 1995-05-18 Fred Hutchinson Cancer Research Center Cytokines hybrides
WO1997010338A1 (fr) * 1995-09-12 1997-03-20 Chiron Corporation Antagoniste ameliore du recepteur de l'interleukine 6

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARCONE R ET AL: "INTERNAL DELETIONS OF AMINO ACIDS 29-42 OF HUMAN INTERLEUKIN-6 IL-6 DIFFERENTIALLY AFFECT BIOACTIVITY AND FOLDING", FEBS, vol. 288, no. 1-2, 1991, pages 197 - 200, XP002246561, ISSN: 0014-5793 *
BRAKENHOFF J P J ET AL: "Analysis of Human IL-6 Mutants Expressed in Escherichia coli.", JOURNAL OF IMMUNOLOGY, vol. 143, no. 4, 15 August 1989 (1989-08-15), pages 1175 - 1182, XP001040401, ISSN: 0022-1767 *
WLASCHEK MEINHARD ET AL: "UVA-induced autocrine stimulation of fibroblast-derived collagenase by IL-6: A possible mechanism in dermal photodamage?", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 101, no. 2, 1993, pages 164 - 168, XP008019164, ISSN: 0022-202X *

Also Published As

Publication number Publication date
EP1451222A2 (fr) 2004-09-01
EP1451222B1 (fr) 2008-09-10
FR2833011A1 (fr) 2003-06-06
US7414024B2 (en) 2008-08-19
US20050158317A1 (en) 2005-07-21
WO2003048205A2 (fr) 2003-06-12
JP2005524606A (ja) 2005-08-18
ATE407947T1 (de) 2008-09-15
DE60228878D1 (de) 2008-10-23
AU2002365646A1 (en) 2003-06-17
FR2833011B1 (fr) 2004-10-29

Similar Documents

Publication Publication Date Title
WO2003012105A3 (fr) Isoforme de facteur de croissance
WO2004043382A3 (fr) Variants ameliores de l'erythropoietine et methodes d'utilisation
EP1803733A3 (fr) Traitement de l'inflammation
CA2257133A1 (fr) Variantes hyperactives de la desoxyribonuclease i humaine
WO2002024234A3 (fr) Utilisation de vecteurs recombines d'administration genique pour traiter ou prevenir des maladies de l'oeil
AU2002365646A1 (en) Novel proteins with il-6 inhibiting activity
WO2002061076A1 (fr) Proteine associee a l'adiponectine
WO2001068854A3 (fr) Molecules s'apparentant au facteur de croissance des fibroblastes et leurs utilisations
WO2002101052A3 (fr) Salutaridinol 7-o-acetyltransferase et derives de celle-ci
BG106008A (en) Novel lhrh antagonists with improved solubility characteristics
WO2002062304A3 (fr) Agents cosmetiques et/ou pharmaceutiques
WO2003070751A3 (fr) Mimetiques peptidiques partiels et procedes associes
CA2340934A1 (fr) Nouvelle collectine
WO2001068676A3 (fr) Nouveaux antagonistes de la lhrh, sa production et son utilisation comme medicament
AU2487602A (en) Isolated luciferases and the use thereof
WO2001059120A3 (fr) Molecules de type il-17 et utilisation de ces dernieres
WO2001010893A3 (fr) Antagonistes de l'interleukine-16
WO2003044047A3 (fr) Genes de virulence, proteines, et leurs utilisations
WO2001092468A3 (fr) Nouvelles compositions pour l'expression du transporteur 1 d'histidine de peptide humain et leurs procedes d'utilisation
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
WO2002070563A3 (fr) Domaine de liaison de ligand au recepteur hormonal nucleaire
WO2001014415A3 (fr) Gènes egfh2 et produits géniques
WO2005105838A3 (fr) Canal ionique
WO2004000870A3 (fr) Deux peptides synthetiques pour le traitement et la prevention de cancers
WO2002018536A3 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003549392

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002804246

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002804246

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10496793

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002804246

Country of ref document: EP